The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market

Pune, India -- (SBWire) -- 05/29/2018 --Global Injectable Drug Delivery Market is estimated to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market

Segmentation: Global Injectable Drug Delivery Market

Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Application (Hormonal Disorders, oncology, autoimmune diseases, orphan disease, other applications), Usage Pattern (Curative Care, Immunizations, Other Usage Pattern ), Mode Of Administration (Skin, Circulatory/ Muskoskeletal, Organs, Central Nervous System ), End User (Hospitals And Clinics, Home Healthcare Settings, Research Laboratories, Pharmaceutical And Biotechnological Companies, Other End Users), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tender, Online Pharmacy),Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Data Bridge Market Research offerings publish report of "Global Injectable Drug Delivery Market" Avail 10% Discount on Direct Purchase Or kindly send the email @ sopan.gedam@databridgemarketresearch.com

Drivers: Global Injectable Drug Delivery Market

RISING CASES OF CHRONIC DISEASES

In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) across the globe has increased considerably over a period of time. The rapidly increasing aging population and the subsequent rise in chronic conditions are major factors driving the demand for and cost of healthcare. This increase in prevalence of chronic diseases has resulted in a significant increase in the demand for self-injectables as these devices are more convenient and safe to be use at home.

This increase in prevalence of chronic diseases can be attributed to unhealthy lifestyles, including excess consumption of alcohol and tobacco. The above-mentioned factors also increase health risks such as obesity, high blood pressure, and cholesterol, which in turn contribute towards the unprecedented rise in cases of chronic diseases.

Mention below is some of the statistics related to the chronic diseases.

- According to Centers for Disease Control and Prevention (CDC), stated that in America, each year 7 of 10 deaths are caused due to chronic diseases.

- According to World Health Organization, in 2016, 71 million people were affected globally by chronic hepatitis C infection.

- According to American Cancer Society, Inc., in 2016, it was estimated that in the U.S. around 1,685,210 new cases of cancer will be diagnosed and approximately 595,690 people will die due to this disease.

- According to World Federation of Hemophilia, in 2015, it was estimated that 187,183 people were suffering from Hemophilia globally.

- According to World Health Organization, in 2014, the prevalence of diabetes over the age of 18 years has increased to 8.5%.

- According to the European Commission, in 2012, chronic diseases in Europe accounted for 86% of all deaths.

- According to National Cancer Institute, cancer is considered as one of the leading causes of death globally. Around 8.8 million cancer-related deaths were reported globally in 2015.

- According to the Australian Institute of Health and Welfare, in 2011, chronic diseases were the leading cause of illness, disability, and death in Australia and it accounted for 90% of all deaths.

- According to American Academy of Dermatology, in the U.S. around 7.5 million people have psoriasis.

- According to Asthma and Allergy Foundation of America, allergies are increasing and they affect around 30% of adults and 40% of children. Allergy is the most common health concern for children in the U.S.

Have Any Query? Ask Our Expert: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market

Mention below is healthcare cost spend on chronic diseases:

- In the European Union, an estimated USD 778.06 billion is spent per year on treating chronic diseases. Many of these chronic diseases require frequent medical aid.
- According to Centers for Disease Control and Prevention (CDC), around 86% of the healthcare costs in the U.S. are for treating people with chronic diseases.

With the increasing prevalence of chronic diseases, the demand for development and innovation of injectable drugs and devices is increasing. This growing demand has provided an opportunity for the pharmaceutical companies to focus on introducing various products in the market in order to meet the rising demand for injectable drug delivery systems. Due to this rising demand the pharmaceutical companies are focusing on developing formulation and devices for maximum utilization of drugs, reduction in health care costs through shorter treatment period, improved therapy, and less frequency of dosing in order to improve various chronic conditions like heart disease, cancer and diabetes which are the leading cause of mortality in the world. Also, as injectable are increasingly proving effective with rapid and effective dosage for such diseases, the market for injectable drug delivery is likely to grow at a higher rate in the coming years

RISING DEMAND OF SELF-INJECTION DEVICES

Self-injection devices are a combination of automatic injection systems with audio-visual guides for surgeries; this includes safety syringes and hidden needles, among others. It has also emerged as one of the fastest growing areas for unit dose medication in order to minimize drug waste and increase product lifespan. As patients are able to self-administer injectable drugs at their home instead of the regular visits to the hospital it improves safety and patient compliance, thus, making the injections easy, safe and convenient. It reduces anxiety eliminating needle phobia through various self-injection devices like auto injectors, pen injectors, needle-free injectors and wearable injectors. These self-injection devices imparts the drug faster and has better reproducibility as compared to invasive drug delivery systems and hence enhance bioavailability when compared with invasive drug delivery systems.

With the existence of a large number of injectable drugs and higher demand for self-injectables from patients, many pharmaceutical players are introducing innovative self-administration therapies. In February 2013, Novo Nordisk launched NovoSeven (Recombinant factor VIIa) with a prefilled syringe system that is used for the treatment of hemophilia. Also, Autoject 2 is an automated injection device of Owen Mumford Company enabling effective drug delivery at a touch of a button to encourage patient's self-reliance by concealing the needle in order to guard against accidental injury.

Major Players: Global Injectable Drug Delivery Market

Some of the major players operating in this market are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd., Ypsomed, and Bespak, among other players.

Questions? We'll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-injectable-drug-delivery-market

TABLE OF CONTENTS GLOBAL INJECTABLE DRUG DELIVERY MARKET

1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY

6.1. OVERVIEW

6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)

7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

7.1. OVERVIEW

7.2. INJECTABLE DRUG DELIVERY DEVICES

7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS

7.3. INJECTABLE DRUG DELIVERY FORMULATION

7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS

7.3.2. NOVEL DRUG DELIVERY FORMULATIONS

7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION

8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS

8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES

8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN'S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS

8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN

10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM

11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS

12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY

13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. OVERVIEW
13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.2.1. U.S. INJECTABLE DRUG DELIVERY MARKET
13.2.2. CANADA INJECTABLE DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTABLE DRUG DELIVERY MARKET

13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET

13.3.1. GERMANY INJECTABLE DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTABLE DRUG DELIVERY MARKET
13.3.3. UK INJECTABLE DRUG DELIVERY MARKET
13.3.4. ITALY INJECTABLE DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTABLE DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTABLE DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET

13.4. APAC INJECTABLE DRUG DELIVERY MARKET

13.4.1. JAPAN INJECTABLE DRUG DELIVERY MARKET
13.4.2. CHINA INJECTABLE DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET
13.4.4. INDIA INJECTABLE DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTABLE DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTABLE DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTABLE DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTABLE DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTABLE DRUG DELIVERY MARKET

13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.5.1. BRAZIL INJECTABLE DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.6. MEA INJECTABLE DRUG DELIVERY MARKET

13.6.1. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTABLE DRUG DELIVERY MARKET

14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

14.1. COMPANY SHARE ANALYSIS: GLOBAL

15. COMPANY PROFILES

15.1. BECTON, DICKINSON AND COMPANY
15.2. PFIZER
15.3. BAXTER INTERNATIONAL
15.4. GERRESHEIMER AG
15.5. SCHOTT AG INC.
15.6. ALKERMES INC.
15.7. ANTARES PHARMA
15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
15.9. ELCAM MEDICAL
15.10. ELI LILLY AND COMPANY
15.11. HASELMEIER
15.12. MYLAN N.V.
15.13. NOVO NORDISK
15.14. OWEN MUMFORD LTD
15.15. SANDOZ INTERNATIONAL GMBH
15.16. SANOFI

16. RELATED REPORTS

Looking for more insights from this report? click the link below @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

Other Market Insights:

North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.

Read More: http://databridgemarketresearch.com/reports/north-america-injectable-drug-delivery-market/

About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com